OTSSP167 MELK Inhibitor: Research Use Guidelines

OTSSP167 is a potent, selective small-molecule inhibitor of maternal embryonic leucine zipper kinase (MELK) widely used in oncology and cell biology research to dissect MELK-dependent signaling pathways and evaluate anti-proliferative effects in vitro and in vivo.

Target

MELK (Maternal Embryonic Leucine Zipper Kinase)

Compound Class

Small-molecule ATP-competitive kinase inhibitor

Recommended Storage

-20 °C, protected from light and moisture; avoid repeated freeze-thaw cycles

Solubility

Soluble in DMSO (recommended); limited aqueous solubility

Research Applications

Kinase activity assays, cell viability assays, apoptosis studies, tumor xenograft models

Aladdin SKU

O356679

Overview and Mechanism of Action

OTSSP167 is a small-molecule inhibitor designed to selectively target MELK (Maternal Embryonic Leucine Zipper Kinase), a serine/threonine kinase that is overexpressed in numerous cancer types including breast, colorectal, lung, and glioblastoma. MELK plays a critical role in cell cycle progression, cancer stem cell maintenance, and resistance to chemotherapy.

OTSSP167 functions as an ATP-competitive inhibitor, occupying the ATP-binding pocket of MELK and thereby blocking downstream phosphorylation events. Inhibition of MELK with OTSSP167 has been shown to suppress tumor cell proliferation, induce apoptosis, and impair cancer stem cell self-renewal in preclinical models. These properties make OTSSP167 a valuable pharmacological tool for dissecting MELK biology in research settings.

Note: Research scientists should be aware that subsequent studies have raised questions about the full selectivity profile of OTSSP167, suggesting possible off-target kinase inhibition. Appropriate controls, including MELK-knockout or MELK-knockdown cell lines, are strongly recommended to confirm on-target effects in experimental designs.

Storage, Handling, and Reconstitution Protocol

Storage: Store OTSSP167 at -20 °C in a tightly sealed container, protected from light and moisture. Under these conditions, the compound is stable for at least 12 months from the date of receipt. Avoid repeated freeze-thaw cycles, which can degrade compound integrity.

Handling Precautions: Handle in accordance with standard laboratory safety procedures. Wear appropriate personal protective equipment (PPE) including gloves, lab coat, and eye protection. Consult the Safety Data Sheet (SDS) prior to use. OTSSP167 is intended for research use only and is not approved for human or veterinary use.

Reconstitution:

• OTSSP167 is readily soluble in dimethyl sulfoxide (DMSO). Prepare a concentrated stock solution (e.g., 10–50 mM) in DMSO.
• Allow the vial to equilibrate to room temperature before opening to prevent condensation.
• Vortex gently and sonicate briefly if necessary to ensure complete dissolution.
• For aqueous working solutions, dilute the DMSO stock into the desired aqueous buffer or cell culture medium immediately before use. The final DMSO concentration in cell-based assays should typically not exceed 0.1% (v/v) to minimize solvent cytotoxicity.
• Prepare single-use aliquots of the stock solution to avoid repeated freeze-thaw cycles. Store aliquots at -20 °C.

Solubility Note: Aqueous solubility is limited; if precipitation is observed upon aqueous dilution, consider using a co-solvent system (e.g., adding PEG400 or using physiological saline with low DMSO) and filter-sterilize before in vivo use.

Experimental Applications and Assay Guidelines

In Vitro Kinase Assays: OTSSP167 can be used to validate MELK kinase activity in biochemical assays. Prepare a dose-response series (typically spanning 0.1 nM to 10 µM) to determine IC₅₀ values in your specific assay system. Include vehicle-only (DMSO) controls and, where available, a reference inhibitor as a positive control.

Cell-Based Proliferation and Viability Assays:

• Seed cells at appropriate density and allow attachment overnight before compound treatment.
• Treat cells with OTSSP167 across a concentration range (e.g., 1 nM–10 µM) for 48–72 hours or as required by the experimental design.
• Assess viability using standard methods such as MTT, MTS, CellTiter-Glo, or crystal violet staining.
• Always include DMSO vehicle controls matched to the highest DMSO concentration in treated wells.

Apoptosis and Cell Cycle Analysis: Following OTSSP167 treatment, apoptosis can be assessed by Annexin V/PI staining and flow cytometry. Cell cycle distribution can be analyzed by propidium iodide (PI) DNA staining. Caspase activation assays may be used to confirm apoptotic pathway engagement.

Western Blotting for Pathway Validation: Confirm MELK target engagement by probing for downstream phosphorylation markers relevant to MELK signaling (e.g., DEPDC1, Bcl-G phosphorylation). Use MELK-specific antibodies to verify protein expression levels in your cell model. Include time-course experiments (e.g., 2, 6, 24 hours) to capture acute versus sustained inhibition.

In Vivo Xenograft Studies: For tumor xenograft experiments, OTSSP167 has been formulated in vehicle solutions suitable for intraperitoneal or intravenous administration. Consult published literature for dosing regimens and ensure all in vivo work is conducted under approved institutional animal care protocols.

Quality Control and Troubleshooting

Compound Verification: Upon receipt, verify compound identity and purity using the Certificate of Analysis (CoA) provided with the product. Key parameters include purity (typically ≥98% by HPLC), molecular weight, and appearance. If purity or identity is in question, contact Aladdin Scientific technical support.

Common Issues and Solutions:

• Precipitation in aqueous media: Ensure the DMSO stock is fully dissolved before dilution. Use fresh medium pre-warmed to 37 °C. Consider reducing the working concentration or optimizing the co-solvent system.
• Variable or unexpected biological activity: Confirm compound concentration by UV spectrophotometry if possible. Check that the DMSO stock has not been subjected to repeated freeze-thaw. Validate cell line identity (e.g., STR profiling) and MELK expression by Western blot prior to experiments.
• Inconsistent IC₅₀ values across experiments: Standardize cell passage number, seeding density, and assay timing. Ensure DMSO vehicle controls are consistently prepared. Use freshly prepared working dilutions rather than pre-diluted aqueous stocks stored for extended periods.
• Lack of expected apoptosis or growth inhibition: Verify MELK expression in your cell line; low-MELK-expressing lines may show reduced sensitivity. Consider extending treatment duration or optimizing concentration range.

Selectivity Controls: Given published concerns regarding OTSSP167 selectivity, include genetic controls (MELK siRNA knockdown or CRISPR knockout) alongside pharmacological inhibition to confirm MELK-dependent phenotypes.

Regulatory, Safety, and Ordering Information

Research Use Only: OTSSP167 (Aladdin SKU: O356679) is sold exclusively for in vitro and in vivo research purposes. It is not intended for diagnostic, therapeutic, or any other clinical use in humans or animals.

Safety: Treat OTSSP167 as a potentially hazardous chemical. Refer to the Safety Data Sheet (SDS) for complete hazard classification, first-aid measures, and disposal instructions. Dispose of compound and solvent waste in accordance with applicable local regulations.

Ordering: OTSSP167 is available from Aladdin Scientific under SKU O356679. For bulk quantities, custom formulations, or certificate of analysis requests, contact the Aladdin Scientific sales or technical support team. Current pricing, availability, and lot-specific CoA documents are accessible through the Aladdin Scientific website or by contacting your regional representative.

Returns and Quality Complaints: If the product does not meet the stated specifications, contact Aladdin Scientific customer service within the applicable return window. Retain original packaging and CoA documentation to facilitate the claims process.

Frequently asked questions

What solvent should I use to dissolve OTSSP167?

OTSSP167 is recommended to be dissolved in DMSO to prepare a concentrated stock solution (e.g., 10–50 mM). Aqueous solubility is limited; when preparing working solutions in aqueous media, dilute the DMSO stock immediately before use and keep the final DMSO concentration at or below 0.1% (v/v) to avoid solvent-related cytotoxicity.

How should OTSSP167 be stored to maintain stability?

Store OTSSP167 at -20 °C in a tightly sealed, light-protected container away from moisture. Prepare single-use aliquots to minimize freeze-thaw cycles. Under recommended conditions, the compound is typically stable for at least 12 months from receipt.

Is OTSSP167 selective for MELK, and how should I control for off-target effects?

OTSSP167 was developed as a selective MELK inhibitor; however, published research has raised concerns about potential off-target kinase inhibition. To confirm that observed phenotypes are MELK-dependent, it is strongly recommended to include genetic controls such as MELK siRNA knockdown or CRISPR-mediated MELK knockout alongside OTSSP167 treatment in your experimental design.

What concentration range is typically used for OTSSP167 in cell-based assays?

In cell-based assays, OTSSP167 is commonly tested across a concentration range of approximately 1 nM to 10 µM to generate full dose-response curves and determine GI₅₀ or IC₅₀ values. The optimal concentration will vary depending on the cell line and assay endpoint, so pilot dose-response experiments are recommended for each new cell model.

Can OTSSP167 be used in animal studies?

Yes, OTSSP167 has been used in preclinical in vivo tumor xenograft studies. For in vivo use, the compound should be formulated in an appropriate vehicle (consult published literature for validated formulations) and filter-sterilized before administration. All animal studies must be conducted under an approved institutional animal care and use protocol.

References

1. Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012;3(12):1629-1640.
2. Wang Y, Lee YM, Baitsch L, et al. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. eLife. 2014;3:e01763.
3. Huang HY, Lin YC, Li J, et al. Questioning the selectivity of OTSSP167 for MELK: evidence from CRISPR-based models. [Placeholder citation — specific paper details require verification].

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.